The FMHR traders weigh in on how to play today's weak manufacturing numbers; Goldman's call on an eight-percent drop in the S&P. Also, China's soft economic data. And Mark Schoenebaum, ISI Group analyst, discusses the merger between Bristol-Myers and Amylin Pharma and whether the pharma sector is on the verge of consolidation.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT